Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?

active surveillance anxiety coping strategies personality traits prostate cancer

Journal

Frontiers in psychology
ISSN: 1664-1078
Titre abrégé: Front Psychol
Pays: Switzerland
ID NLM: 101550902

Informations de publication

Date de publication:
2020
Historique:
received: 26 06 2020
accepted: 28 09 2020
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 29 12 2020
Statut: epublish

Résumé

The psychological burden possibly deriving from not immediately undergoing radical treatment for prostate cancer (PCa) could be a potential disadvantage of active surveillance (AS), especially in the eve of some relevant clinical exams [i.e., re-biopsy, prostate-specific antigen (PSA) test, and medical examination]. Even if it is known from the literature that the majority of PCa men in AS do not report heightened anxiety, there is a minority of patients who show clinically significant levels of anxiety after diagnosis. The present study aimed to investigate if demographic, clinical, and psychological variables at the entrance in AS (T0) were associated with the risk of developing clinically significant PCa-related anxiety 2 months before the first re-biopsy (T1) and to offer psychological support to improve quality of life (QoL). A total of 236 patients participated in the PCa Research International: AS (PRIAS) protocol and in PRIAS-QoL study. Demographic/clinical features, health-related QoL domains, coping with cancer, PCa-related anxiety [Memorial Anxiety Scale for PCa (MAX-PC)], personality traits, and decision-making-related factors were assessed at T0. MAX-PC was also administered at T1. PCa-related anxiety at T1 was considered to be of clinical significance if the MAX-PC score was ≥1.5. Multivariable logistic regression coupled to bootstrap was used to detect factors associated with high levels of anxiety. The median age was 64.4 years. Fifty-six patients (24%) reported MAX-PC total score above the cutoff. Three factors were associated with a high level of PCa anxiety at T1: anxious preoccupation [odds ratio (OR) = 4.36], extraversion (OR = 1.9), and prostate-related symptoms (median OR = 0.46). Physical well-being was associated with a low PCa anxiety subscale (median OR = 0.15); neuroticism and functional well-being were associated with PSA anxiety (median OR = 7.05 and 0.73, respectively). Neuroticism and helplessness/hopelessness were associated with fear of progression (median OR = 18.1 and 5.8, respectively). Only a partial portion of the sample experienced significant levels of anxiety after 10 months. Psychological assessment should be routinely conducted to detect risk factors (i.e., anxious preoccupation, extraversion) for increased anxiety, offering tailored psychological interventions aimed at promoting interpersonal awareness and emotional well-being.

Sections du résumé

BACKGROUND BACKGROUND
The psychological burden possibly deriving from not immediately undergoing radical treatment for prostate cancer (PCa) could be a potential disadvantage of active surveillance (AS), especially in the eve of some relevant clinical exams [i.e., re-biopsy, prostate-specific antigen (PSA) test, and medical examination]. Even if it is known from the literature that the majority of PCa men in AS do not report heightened anxiety, there is a minority of patients who show clinically significant levels of anxiety after diagnosis. The present study aimed to investigate if demographic, clinical, and psychological variables at the entrance in AS (T0) were associated with the risk of developing clinically significant PCa-related anxiety 2 months before the first re-biopsy (T1) and to offer psychological support to improve quality of life (QoL).
MATERIALS AND METHODS METHODS
A total of 236 patients participated in the PCa Research International: AS (PRIAS) protocol and in PRIAS-QoL study. Demographic/clinical features, health-related QoL domains, coping with cancer, PCa-related anxiety [Memorial Anxiety Scale for PCa (MAX-PC)], personality traits, and decision-making-related factors were assessed at T0. MAX-PC was also administered at T1. PCa-related anxiety at T1 was considered to be of clinical significance if the MAX-PC score was ≥1.5. Multivariable logistic regression coupled to bootstrap was used to detect factors associated with high levels of anxiety.
RESULTS RESULTS
The median age was 64.4 years. Fifty-six patients (24%) reported MAX-PC total score above the cutoff. Three factors were associated with a high level of PCa anxiety at T1: anxious preoccupation [odds ratio (OR) = 4.36], extraversion (OR = 1.9), and prostate-related symptoms (median OR = 0.46). Physical well-being was associated with a low PCa anxiety subscale (median OR = 0.15); neuroticism and functional well-being were associated with PSA anxiety (median OR = 7.05 and 0.73, respectively). Neuroticism and helplessness/hopelessness were associated with fear of progression (median OR = 18.1 and 5.8, respectively).
CONCLUSION CONCLUSIONS
Only a partial portion of the sample experienced significant levels of anxiety after 10 months. Psychological assessment should be routinely conducted to detect risk factors (i.e., anxious preoccupation, extraversion) for increased anxiety, offering tailored psychological interventions aimed at promoting interpersonal awareness and emotional well-being.

Identifiants

pubmed: 33363494
doi: 10.3389/fpsyg.2020.576459
pmc: PMC7753742
doi:

Types de publication

Journal Article

Langues

eng

Pagination

576459

Informations de copyright

Copyright © 2020 Alvisi, Dordoni, Rancati, Avuzzi, Nicolai, Badenchini, De Luca, Magnani, Marenghi, Menichetti, Silvia, Fabiana, Roberto, Riccardo, Lara and the Prostate Cancer Multidisciplinary Clinic Working Group.

Références

J Psychosoc Oncol. 2017 Jan-Feb;35(1):17-31
pubmed: 27541961
Med Decis Making. 1995 Jan-Mar;15(1):25-30
pubmed: 7898294
Eur Urol. 2017 Feb;71(2):274-280
pubmed: 27720532
BJU Int. 2012 Oct;110(7):998-1003
pubmed: 22404874
Urology. 1997 Dec;50(6):920-8
pubmed: 9426724
J Urol. 2018 Dec;200(6):1250-1255
pubmed: 29886089
Psychooncology. 2015 Mar;24(3):348-54
pubmed: 25138075
Tumori. 2018 Jun;104(3):172-178
pubmed: 28623635
Eur Urol. 2016 Dec;70(6):954-960
pubmed: 27329565
Depress Anxiety. 2006;23(5):281-9
pubmed: 16688731
BJU Int. 2016 Mar;117(3):469-77
pubmed: 25714186
Crit Rev Oncol Hematol. 2013 Mar;85(3):295-302
pubmed: 22878262
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Tumori. 2017 Sep 18;103(5):464-474
pubmed: 28623636
Cancer. 2009 Sep 1;115(17):3868-78
pubmed: 19637245
BJU Int. 2014 Nov;114 Suppl 1:55-61
pubmed: 25070423
Eur Urol. 2015 Apr;67(4):637-45
pubmed: 25454617
Cancer. 2003 Jun 1;97(11):2910-8
pubmed: 12767107
Psychosomatics. 2006 Jul-Aug;47(4):340-7
pubmed: 16844894
Urology. 2004 Apr;63(4):751-6
pubmed: 15072894
J Urol. 2016 Jun;195(6):1724-30
pubmed: 26872841
Eur Urol. 2013 Jul;64(1):30-6
pubmed: 23357351
Radiother Oncol. 2016 Jan;118(1):92-8
pubmed: 26777123
J Clin Oncol. 2015 Jan 20;33(3):272-7
pubmed: 25512465
Urology. 1997 Dec;50(6):831-2
pubmed: 9426708
Support Care Cancer. 2021 Feb;29(2):645-651
pubmed: 32424643

Auteurs

Maria Francesca Alvisi (MF)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Paola Dordoni (P)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Tiziana Rancati (T)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Barbara Avuzzi (B)

Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Nicola Nicolai (N)

Department of Urology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Fabio Badenchini (F)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Letizia De Luca (L)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Tiziana Magnani (T)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Cristina Marenghi (C)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Julia Menichetti (J)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Villa Silvia (V)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Zollo Fabiana (Z)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Salvioni Roberto (S)

Department of Urology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Valdagni Riccardo (V)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Bellardita Lara (B)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Classifications MeSH